In recent years, monoclonal antibodies blocking the inhibitory programmed cell death 1 pathway (PD-1/PD-L1) and the cytotoxic T lymphocyte associated protein 4 (CTLA-4) have significantly impacted the treatment of advanced melanoma. The gene discussed is PDCD1; the disease is melanoma.